Measuring severe adverse events and medication selection using a “PEER Report” for nonpsychotic patients: a retrospective chart review
Daniel A Hoffman,1 Charles DeBattista,2 Rob J Valuck,3 Dan V Iosifescu41Neuro-Therapy Clinic, Inc, Denver, CO, USA; 2Stanford University School of Medicine, Palo Alto, CA, USA; 3University of Colorado, SKAGES School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA; 4Mood and Anxiety Disorder...
Guardado en:
Autores principales: | Hoffman DA, DeBattista C, Valuck RJ, Iosifescu DV |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4bd0171a5162435a93c06eb954a42ab5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to personalize pharmacotherapy
por: Iosifescu DV, et al.
Publicado: (2016) -
Who coined the term “status gelasticus”? We did
por: Yu-tze Ng
Publicado: (2009) -
Retrospective chart review of a referenced EEG database in assisting medication selection for treatment of depression in patients with eating disorders
por: Greenblatt JM, et al.
Publicado: (2011) -
Letter to the editor regarding the article “The use of Psychiatric Electroencephalography Evaluations Registry (PEER) to personalize pharmacotherapy”
por: Weina PJ, et al.
Publicado: (2017) -
Daunorubicin-TiO2 nanocomposites as a “smart” pH-responsive drug delivery system
por: Zhang H, et al.
Publicado: (2012)